تطوير وتقييم صيغ صيدلانية مقترحة لحثيرات معدلة التحرر حاوية على السيليكوكسيب لاستخدامها في تحضير مضغوطات ذات تحرر مديد

أحمد الخضري

doi:10.5281/zenodo.20237593

Authors

Dr. Ahamed Alkhodri Al Wataniya Private University Author

DOI:

https://doi.org/10.5281/zenodo.20237593

Keywords:

Celecoxib, Granules, Tablets, Dissolution test, Extended release

Abstract

Objective: Procedure a technological study for proposed pharmaceutical formulations for preparing prolonged release granules of celecoxib for reducing of chronic pain for use it in preparation other pharmaceutical
dosage forms.
Materials and Methods: The research experiments were conducted by using materials and calibrated accurately devices according to the requirements of Good Manufacturing Practice (GMP). The technological properties of prepared pharmaceutical dosage forms as granules and tablets were determined by doing pharmacopoeial tests according to the requirements of the United States Pharmacopoeia USP 43 NF 38. Cellulose polymers as an auxiliary excipient, were selected to control the release of celecoxib. Six formulations of celecoxib granules were proposed and their technological properties and release rate were determined by dissolution test in Vitro. Their suitability for obtaining tablets with extended release as a final pharmaceutical dosage form was also determined.
Results: The results showed that 3 of the proposed formulations give promising results for manufacturing a prolonged-acting pharmaceutical dosage form of celecoxib for prolonged pain relief up to 20 hours, and clinical tests can be continued on these formulations.
Conclusion: This current study shed light on the possibility of preparing extended release tablets of celecoxib used as a newer generation selective non-steroidal anti-inflammatory for the treatment of chronic pain. These prepared pharmaceutical dosage forms are expected to reduce the severity of side effects with improving patient adherence to the treatment plan, also reducing the frequency of administration compared to conventional pharmaceutical forms, and reducing treatment costs.

Downloads

Download data is not yet available.

References

[1] N. B. Demina, “Modern trends in development of the technology of matrix drug dosage forms with modified release (a review),” Pharmaceutical Chemistry Journal, vol. 50, no. 7, pp. 44–50, 2016, doi: 10.30906/0023-1134-2016-50-7-44-50.

[2] World Health Organization (WHO), “Musculoskeletal conditions.” [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions.

[3] J. M. Hootman, C. G. Helmick, K. E. Barbour, K. A. Theis, and M. A. Boring, “Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015–2040,” Arthritis & Rheumatology, vol. 68, no. 7, pp. 1582–1587, 2016, doi: 10.1002/art.39692.

[4] I. N. Samartsev, S. A. Zhivolupov, and R. Z. Nazhmudinov, “Identification of non-steroidal anti-inflammatory drugs as a necessity basis of effectiveness and risk correlation conception,” Zhurnal Nevrologii i Psikhiatrii im. S. S. Korsakova, vol. 119, no. 12, pp. 124–131, 2019, doi: 10.17116/jnevro2019119121124.

[5] F. Meng, R. Ferreira, and F. Zhang, “Effect of surfactant level on properties of celecoxib amorphous solid dispersions,” Journal of Drug Delivery Science and Technology, vol. 49, pp. 301–307, 2019, doi: 10.1016/j.jddst.2018.11.026.

[6] Pfizer Inc., “Celecoxib compositions,” U.S. Patent RE44048. [Online]. Available: http://labeling.pfizer.com/ShowLabeling.aspx?id=793.

[7] European Patent Office, “Celecoxib compositions,” EP 1049467 B1.

[8] M. V. Grigor’yeva, “Polymer systems with controlled release of bioactive compounds,” Biotechnologia Acta, vol. 4, no. 2, 2011.

[9] P. Salve, S. Aherrao, and N. Bali, “Development and evaluation of sustained release dosage form using hydrophilic and hydrophobic materials,” Research Journal of Pharmacy and Technology, vol. 9, no. 5, pp. 481–489, 2016, doi: 10.5958/0974-360X.2016.00089.5.

[10] X. Qi et al., “Floating tablets for controlled release of ofloxacin via compression coating of hydroxypropyl cellulose combined with effervescent agent,” International Journal of Pharmaceutics, vol. 489, no. 1–2, pp. 210–217, 2015, doi: 10.1016/j.ijpharm.2015.05.007.

[11] K. A. A. Abdulhameed and N. A. Salih, “Controlled release of cefixime using sodium carboxymethyl cellulose polymer,” Research Journal of Pharmacy and Technology, vol. 12, no. 9, pp. 4073–4079, 2019, doi: 10.5958/0974-360X.2019.00701.7.

[12] F. Zhang, F. Meng, Z. Y. Wang, and W. Na, “Interpolymer complexation between copovidone and carbopol and its effect on drug release from matrix tablets,” Drug Development and Industrial Pharmacy, vol. 43, no. 2, pp. 190–203, 2017, doi: 10.1080/03639045.2016.1230625.

[13] S. K. Paulson et al., “Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 2, pp. 638–645, 2001.

[14] United States Pharmacopeial Convention, USP 43–NF 38, 2022. [Online]. Available: https://www.uspnf.com/notices/usp-43-nf-38-online-table-contents-admissions.

[15] P. Thapa, A. R. Lee, D. H. Choi, and S. H. Jeong, “Effects of moisture content and compression pressure of various deforming granules on the physical properties of tablets,” Powder Technology, vol. 310, pp. 92–102, 2017, doi: 10.1016/j.powtec.2017.01.021.

[16] L. Fitriani, R. Abdillah, and E. S. Ben, “Formulation of metformin HCl floating tablet using HPC, HPMC K100M, and the combinations,” Jurnal Sains Farmasi & Klinis, vol. 4, no. 1, pp. 79–82, 2017, doi: 10.29208/jsfk.2017.4.1.201.

[17] S. Suslina and A. Alkhodri, “Preparation, evaluation and development celecoxib prolonged release (PR) tablets by using cellulose polyacrylic acid-based polymers,” Research Journal of Pharmacy and Technology, vol. 15, no. 4, pp. 1727–1731, 2022, doi: 10.52711/0974-360X.2022.00289.